News Column

New Findings from Nanjing Medical University in the Area of Cancer Gene Therapy Reported

June 23, 2014



By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Data detailed on Biotechnology have been presented. According to news reporting originating from Jiangsu, People's Republic of China, by NewsRx correspondents, research stated, "MUC4/Y, the transcript variant 4 of MUC4, lacks exon 2 as compared with the transcript variant 1 of MUC4. To date, direct evidence for the function of MU4/Y remains to be reported."

Our news editors obtained a quote from the research from Nanjing Medical University, "Previous studies based their hypotheses regarding the function of MUC4/Y on the characteristic structure domains of this variant. The aim of the present study was to investigate the specific function of MUC4/Y. The pancreatic cancer cell line MIA PaCa-2 with low MUC4/Y expression was used to establish a stable cell model of MUC4/Y upregulation using a lentivirus vector system. MUC4/Y anchored on the cytomembrane and affected cell morphology and cell cycle. Functional analyses indicated that MUC4/Y upregulation slightly potentiated cell proliferation and significantly suppressed apoptosis both in vivo and in vitro. Further studies revealed that the JNK and AKT signalling pathways were activated. Meanwhile, MUC4/Y upregulation elicited minimal effect on the phosphorylation level of HER2, a membrane partner of MUC4."

According to the news editors, the research concluded: "These results suggest that MUC4/Y promotes tumor progression through its anti-apoptotic and weak mitogenic effect on MIA PaCa-2 cells."

For more information on this research see: Upregulation of the splice variant MUC4/Y in the pancreatic cancer cell line MIA PaCa-2 potentiates proliferation and suppresses apoptosis: new insight into the presence of the transcript variant of MUC4. Oncology Reports, 2014;31(5):2187-94 (see also Biotechnology).

The news editors report that additional information may be obtained by contacting K. Xie, Dept. of General Surgery, First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu 210029, People's Republic of China. Additional authors for this research include X. Zhi, J. Tang, Y. Zhu, J. Zhang, Z. Li, J. Tao and Z. Xu.

Keywords for this news article include: Asia, Biotechnology, Jiangsu, Oncology, Apoptosis, Gastroenterology, Pancreatic Cancer, Cancer Gene Therapy, Pancreatic Neoplasms, People's Republic of China.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Gene Therapy Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters